MADCAM1 and inflammatory bowel disease: These data suggest that IBD patients treated with Abs that block α4β7 or MAdCAM-1 may benefit from additional integrin and/or inflammatory cytokine blockades to further inhibit inflammatory cell migration to the gut mucosa.